Abstract
Objective : We determined whether GLUT-1 is associated with HIF-1α, CD34-positive microvessel density (MVD), and clinicopathological findings in endometrial adenocarcinomas (EMAC), and whether GLUT-1 is a more useful marker for EMAC Grade 1 diagnosis than endometrial hyperplasia (EH).
Study Design : We performed immunohistochemistry for GLUT-1, HIF-1α, and CD34 in 34 resected EMAC samples and immunohisto/cytochemistry for GLUT-1 in 29 biopsy samples including curettage and cytology in EH and EMAC Grade 1. GLUT-1 expression levels were semiquantitatively evaluated using both the proportion and intensity score.
Results : GLUT-1 expression was found in 53% (9/17) of Grade 1, 91% (10/11) of Grade 2, and 83% (5/6) of Grade 3 resected EMAC samples. GLUT-1 expression was significantly associated with HIF-1α expression and tumor size (P<0.05). GLUT-1 expression was found in no (0/14) EH and 53% (8/15) of EMAC Grade 1 biopsy samples. GLUT-1 expression was found in 7% (1/14) of EH and 60% (9/15) of EMAC Grade 1 cytological samples. GLUT-1 expression differed significantly between EH and EMAC Grade 1 (P<0.05).
Conclusion : GLUT-1 expression appears useful for differential by diagnosing EMAC and EH, and GLUT-1 can be applied to endometrial cytology.
